2019³â ´ëÇѽŰæ±Ù¿¬±¸ÇÐȸ Ãá°èÇмú´ëȸ ¹× ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ °¿øÁöȸ ½ÉÆ÷Áö¾ö : 2019-06-22±³À°ÀÏÀÚ : 2019-06-22
±³À°Àå¼Ò : ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101, 102È£
±³À°ÁÖÁ¦ :
2019³â ´ëÇѽŰæ±Ù¿¬±¸ÇÐȸ Ãá°èÇмú´ëȸ ¹× ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ °¿øÁöȸ ½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇѸ¶ÃëÅëÁõÀÇÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽŰæ±Ù¿¬±¸È¸
´ã´çÀÚ : Çѹμö
¿¬¶ôó : 031-981-2764
À̸ÞÀÏ :
daonics@naver.com ±³À°Á¾·ù : ¸¶ÃëÅëÁõÀÇÇаú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª :
°¿øµµ±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 50,000¿ø
ºñ°í µî·Ïºñ ±¸ºÐ »çÀüµî·Ï ÇöÀåµî·Ï ¿¬È¸ºñ Á¤È¸¿ø(Àü¹®ÀÇ) ¹«·áµî·Ï ¹«·áµî·Ï 50,000¿ø ºñȸ¿ø(Àü¹®ÀÇ) 30,000¿ø 40,000¿ø ¾øÀ½ ½ÅÀÔȸ¿ø(Àü¹®ÀÇ) ¾øÀ½ ¾øÀ½ 50,000¿ø Àü°øÀÇ ¹× ±âŸÀÇ·áÁø 20,000¿ø 30,000¿ø ¾øÀ½
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-22 ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101È£ 09:00~09:25 Clinical applications of neuromuscular monitoring ¼Á¤È(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-22 ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101È£ 09:25~09:50 Current evidence-based recommendations for monitoring and reversal ±èÁø¼±(°¸ª¾Æ»êº´¿ø)
±³À°½Ã°£ 06-22 ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101È£ 09:50~10:15 Malignant hyperthermia and muscle-related disorder ±è±Ô³²(ÇѾçÀÇ´ë)
Åä·Ð 06-22 10:15~10:35 Q & A ()
ÈÞ½Ä 06-22 10:35~10:50 Break ()
±³À°½Ã°£ 06-22 ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101È£ 10:50~11:15 Clinical applications of neuromuscular monitoring ¾çÈ«¼®(´ëÀü ¼±º´¿ø)
±³À°½Ã°£ 06-22 ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101È£ 11:15~11:40 Current evidence-based recommendations for monitoring and reversal ÀÌ¿øÁø(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 06-22 ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101È£ 11:45~12:05 Malignant hyperthermia and muscle-related disorder ÃÖÀç¹®(¿ï»êÀÇ´ë)
Åä·Ð 06-22 12:05~12:25 Q & A ()
½Ä»ç 06-22 12:30~13:30 Lunch ()
±³À°½Ã°£ 06-22 ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101È£ 13:30~13:55 Recent literature review; sugammadex: what do we know and what do we still need to know? Á¤±âÅÂ(Á¶¼±ÀÇ´ë)
±³À°½Ã°£ 06-22 ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101È£ 13:55~14:20 Statistical/methodology: randomization ÀÎÁØ¿ë(µ¿±¹ÀÇ´ë)
Åä·Ð 06-22 14:20~14:35 Q & A ()
ÈÞ½Ä 06-22 14:35~14:50 Break ()
±³À°½Ã°£ 06-22 ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101È£ 14:50~15:10 Retrospective analysis of 30-day unplanned readmission after major abdominal surgery with reversal by sugammadex or neostigmine ¿ÀŹ±Ô(¼¿ïÀÇ´ë)
±³À°½Ã°£ 06-22 ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101È£ 15:10~15:30 Effects of magnesium chloride on rocuronium-induced neuromuscular blockade and sugammadex reversal in an isolated rat phrenic nerve-hemidiaphragm preparation ¼ºÅÂÀ±(°Ç¾çÀÇ´ë)
±³À°½Ã°£ 06-22 ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø Áø¸®°ü 1Ãþ 101È£ 15:30~15:50 Comparison of rocuronium-induced neuromuscular blockade in second trimester pregnant women and non-pregnant women ÀüÀÎÁ¤(ÇѸ²ÀÇ´ë)
Åä·Ð 06-22 15:50~16:10 Q & A ()